Imurel

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Imurel

What is Imurel? Overview

Property Description
Active ingredient Azathioprine
Form Tablet (Oral), Injectable Solution (Intravenous)
Pharmacological class Systemic Immunosuppressant, Purine Antimetabolite
Common use Managing Autoimmune Disease and Transplant Rejection
Origin Synthetic (Chemically Synthesized)

What Type of Medicine is Imurel (Azathioprine)?

Imurel is a prescription-only medication primarily identified by its active ingredient, Azathioprine, a compound classified as a systemic immunosuppressant and a purine antimetabolite. Azathioprine functions as a prodrug that requires metabolism in the body to form its effective compounds. This characteristic means the substance becomes active only after it has been processed internally.

Azathioprine is a foundational medicine used in managing chronic conditions driven by an overactive immune system. Imurel is an internationally recognized brand name for Azathioprine, which is a product of chemical synthesis and is structurally distinguished as a purine analog. The pharmacological classification of Azathioprine as an immunosuppressant is defined by its effects on immune cell function.

Composition and General Purpose of Azathioprine

The composition of Imurel centers on its core agent, Azathioprine, and it is available primarily in two forms: an oral tablet for routine daily use and a sterile injectable solution for intravenous administration in clinical settings. The general therapeutic purpose of the drug is to achieve sustained control over widespread, damaging immune activity.

Azathioprine works by disrupting the ability of certain immune cells, specifically T-lymphocytes and B-lymphocytes, to multiply rapidly. This systemic dampening of the immune response is used to mitigate the ongoing tissue damage characteristic of autoimmune diseases and is utilized for its role in supporting organ transplant recipients.

Why Is Imurel Classified as an Immunosuppressant?

Imurel is classified as an immunosuppressant because its core function is to reduce the overall intensity and functional capability of the body's defensive immune system. This classification is based on its ability to inhibit the growth and cell proliferation of the immune cells that initiate and perpetuate inflammation.

The drug achieves this effect by acting as a purine analog, which is metabolized into products that interfere with the production of DNA essential for cell division. As an established cytotoxic agent, Azathioprine is used to manage serious conditions requiring immune modulation.

Regulatory References

  1. United States National Library of Medicine

What side effects are possible with Imurel?

Possible Side Effects and Safety Information

The official safety profile for Imurel (Azathioprine), a systemic immunosuppressant, emphasizes the risk of serious systemic adverse reactions that necessitate active patient monitoring. The most critical safety domains documented in regulatory labeling are Bone Marrow Suppression and the increased risk of Secondary Malignancy.


Officially Documented Adverse Reactions

The frequency of adverse reactions is classified in regulatory documents according to observed incidence rates:

Classification Examples of Documented Effects
Very Common (ge 10%) Anorexia
Common (1% to 10%) Alopecia
Uncommon (0.1% to 1%) Hypersensitivity reactions, Stevens-Johnson Syndrome

Major System-Organ Classes involved include Blood and Lymphatic System Disorders (e.g., Leukopenia, Thrombocytopenia), Infections and Infestations, Neoplasms (Malignancy), and Gastrointestinal Disorders (e.g., Nausea, Vomiting, Pancreatitis).


Serious Safety Considerations

Official labeling contains specific warnings regarding Severe Bone Marrow Suppression (myelosuppression), which can be life-threatening. The risk of developing Malignancy, including lymphomas, Hepatosplenic T-cell Lymphoma (HSTCL), and non-melanoma skin cancer, is also highlighted, particularly with long-term exposure. The use of Azathioprine is associated with an increased risk of Serious Infections.


Population and Monitoring Constraints

Safety is significantly tied to the patient's genetic status. Individuals with low or absent activity of the TPMT enzyme are at a substantially increased risk for severe toxicity, which may require genetic testing. Gastrointestinal effects are more common at the initiation of treatment. Due to the systemic risks, the regulatory label requires frequent hematologic monitoring (e.g., regular blood counts) and liver function testing throughout the course of therapy. Contraindications include known hypersensitivity and active infection.

Overdose and Emergency Response

The official regulatory profile for an Imurel (Azathioprine) overdose focuses primarily on the risk of severe bone marrow suppression (myelotoxicity), which is a potentially life-threatening event. This hematologic toxicity is often delayed, with the lowest blood cell counts possibly occurring up to nineteen days after the overexposure.

Documented manifestations may include signs such as fever, infections, ulceration of the throat, bruising, and bleeding, along with gastrointestinal effects like nausea, vomiting, and diarrhea.

Because no specific antidote is known for Azathioprine, management consists of symptomatic and supportive treatment. Following overexposure, continuous monitoring of blood count and hepatic function is required.

Immediate medical help must be sought in cases of suspected overdose. Regulators mandate calling emergency services if the individual collapses, has a seizure, or has trouble breathing. Urgent medical attention is required for any emerging symptoms of myelosuppression, as toxicity risk is enhanced by existing renal or hepatic insufficiency or low Thiopurine S-methyl transferase (TPMT) enzyme activity.

Therapeutic Uses of Imurel

Quick Facts: Primary Uses

Condition Therapeutic Goal
Renal Transplant Help prevent organ rejection
Rheumatoid Arthritis (RA) Manage signs and symptoms
Crohn's Disease* Maintain remission; support steroid withdrawal
Ulcerative Colitis* Maintain remission; support steroid withdrawal

Imurel (azathioprine) is a prescription medication utilized in therapeutic regimens primarily designed to modulate the immune system activity in certain patients. Its established role includes serving as an adjunct therapy for individuals receiving a renal organ transplant to help prevent the body from rejecting the new organ.

The medication is also indicated for the management of active adult Rheumatoid Arthritis (RA) to reduce signs and symptoms, such as joint pain and swelling. For patients with RA, the drug may be administered to support the reduction of disease activity.

Furthermore, Imurel is often used in the management of inflammatory bowel diseases like Crohn’s disease and ulcerative colitis (UC) to maintain clinical remission and support a reduction in steroid reliance, providing a helpful long-term support option.

*Note: Use in inflammatory bowel disease is common but may be off-label in some regions. Please consult available prescribing information for the most up-to-date, approved uses.

Eligibility and Restrictions for Use

Azathioprine (Imurel) is an immunosuppressant medicine with strict population eligibility rules defined by regulatory authorities. Use is established for adults in indications such as renal transplant prophylaxis and Rheumatoid Arthritis (RA), and for pediatric patients in transplantation. However, use in children for Juvenile Idiopathic Arthritis is considered not established.

Absolute Contraindications

Regulatory labeling prohibits Azathioprine use in the following populations:

  • Patients with hypersensitivity to the drug or its metabolites.
  • Individuals with a current severe infection or seriously impaired bone marrow function.
  • Women using the medicine for Rheumatoid Arthritis during pregnancy.

Conditional Use Requirements

Special restrictions apply to other groups:

  • Genetic Status: Individuals with absent or low activity of the TPMT or NUDT15 enzymes are at high risk of toxicity and require substantial dose reduction or alternative therapy.
  • Organ Function: Use requires caution and potential dose adjustment in patients with severe hepatic or renal impairment.
  • Reproductive Status: Use is generally not recommended or contraindicated in breastfeeding mothers.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile for Azathioprine (Imurel) is defined by mandatory restrictions and pharmacokinetic management rules documented in regulatory sources.

Contraindicated and High-Risk Combinations

  • Live Vaccines: Co-administration is formally prohibited due to the immunosuppressive effect of Azathioprine, which creates a risk of systemic infection from the vaccine organism.
  • Allopurinol, Oxypurinol, or Thiopurinol: These xanthine oxidase inhibitors cause a major pharmacokinetic interaction. They inhibit the breakdown of Azathioprine's active metabolite, resulting in a significant increase in systemic exposure. Regulatory documents require the Azathioprine dosage to be reduced to 25% of the standard dose if this combination is unavoidable.

Pharmacodynamic and Exposure-Altering Interactions

  • Myelosuppressive Agents: Combining Azathioprine with other cytotoxic or myelosuppressive drugs, including Aminosalicylates (e.g., Mesalazine), carries an additive pharmacodynamic risk of severe bone marrow depression.
  • Warfarin and Coumarin Derivatives: Azathioprine has been officially reported to inhibit the anticoagulant effect of these medicines.
  • Neuromuscular Blocking Agents: Azathioprine may antagonize the effect of non-depolarizing agents and potentiate the effect of depolarizing agents used during surgery.

Population-Specific Considerations

  • TPMT Activity: The risk for severe toxicity and associated interactions is officially amplified in patients with reduced Thiopurine Methyltransferase (TPMT) enzyme activity, a factor noted in regulatory labeling.

This structure defines the critical interaction constraints, from formal prohibitions to required dosage management rules, as established by global government health authorities.

Mechanism of Action

How Imurel Works: The Mechanism of Action


Prodrug Activation and Purine Synthesis Blockade

Imurel functions as an inactive prodrug that requires complex metabolic conversion within the body to form the active metabolites, 6-Thioguanine Nucleotides (6-TGNs). These 6-TGNs act as antimetabolites, directly inhibiting key enzymes, such as Amidophosphoribosyltransferase (ATase), which are essential for the production of purine bases (adenine and guanine). This action deprives rapidly dividing cells of the necessary building blocks for their genetic material, initiating the resulting immunosuppression.


Targeted Blockade of Lymphocyte Proliferation

The central mechanism involves the inhibition of proliferation in T-lymphocytes and B-lymphocytes. The drug's active metabolites are mistakenly incorporated into the DNA and RNA of these rapidly proliferating immune cells, disrupting their ability to replicate successfully and causing them to undergo programmed cell death (apoptosis). This two-pronged action—blocking proliferation and inducing cell death—leads to a systemic reduction in the number and functional capacity of these immune cells.


Physiological Consequence: Systemic Immune Modulation

Because the mechanism relies on the gradual depletion of existing immune cells that cannot be quickly replaced, the resulting systemic immunosuppression is characterized by a delayed onset due to the nature of the cell cycle blockade. This foundational physiological change results in the overall modulation of the cellular-mediated immune response.

Dosage and Administration Information

Official Administration Guidelines

Azathioprine (Imurel) is administered based on specific regimens defined by body weight, with different rules for initiation, maintenance, and special populations.


Administration Scope

Entity Description
Route of Administration Primarily Oral (tablet) for routine use, or Intravenous (IV) injection when the oral route is not feasible.
Dosing Schedule Weight-Based Dosing (mg/kg per day). Initial dose for transplant is 3 to 5 mg/kg per day; maintenance dose is 1 to 4 mg/kg per day. The maximum labeled dose for Rheumatoid Arthritis is 2.5 mg/kg per day.
Timing in relation to meals Tablets should preferably be taken with or after food to lessen stomach upset. The oral suspension may require intake at least 1 hour before or 2 hours after a meal or milk.
Age-group administration rules Older Adults and patients with renal or hepatic impairment are generally advised to use dosages at the lower end of the normal range. Posology for pediatric transplant patients is the same as in adults based on body weight.
Special procedural conditions The dosage must be reduced to 1/4 to 1/3 of the usual dose when administered concurrently with Allopurinol. Individuals with known genetic deficiencies in the TPMT or NUDT15 enzymes may require alternative therapy or dose modification.

Procedural Structure and Duration

Official instructions establish a specific sequence for use:

  • The daily dose is typically taken once daily or, for Rheumatoid Arthritis, may be given in divided doses.
  • Dose adjustments (titration) for conditions like Rheumatoid Arthritis are often made gradually, at intervals of 4 weeks or longer, until the desired maintenance level is reached.
  • Therapy for organ transplantation is typically maintained indefinitely due to the nature of the condition.
  • For other conditions, such as Rheumatoid Arthritis, a minimum duration of 12 weeks is generally required before therapeutic effect is evaluated and dose changes or withdrawal are considered.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Imurel (Azathioprine)


Evidence for Use in Kidney Transplant Management

Research examined Azathioprine's use in the context of immunosuppressive protocols for kidney organ rejection. The research base is long-standing and includes historical controlled trials and extensive long-term observational cohort studies. Researchers examined Azathioprine primarily as a component of a multi-drug regimen, often referred to as "triple therapy."

The main outcomes research examined were the long-term survival of the transplanted organ (known as graft survival) and the survival of the patient. Studies also monitored the frequency of sudden or acute rejection episodes. Research describes patterns observed in the studies regarding patient and organ survival that extend over several years when used as part of these complex protocols.


Evidence for Use in Rheumatoid Arthritis

Research for managing active Rheumatoid Arthritis (RA) in adults primarily involves Randomized Controlled Trials (RCTs) and subsequent analyses that combine data from these trials. These studies was studied for patients with conditions where symptoms may vary in intensity and was evaluated in settings exploring outcomes when initial therapies haven't produced measured change.

The trials monitored outcomes related to physical discomfort and daily functioning by measuring changes in the number of tender joints and swollen joints, along with patient-reported outcomes describing perceived discomfort. Evidence is limited regarding the long-term effects. Data for long-term outcomes, such as sustained functional ability or whether the medicine influences joint damage visible on imaging, are not fully established or well-characterized by the existing trial data.


Evidence for Use in Inflammatory Bowel Disease

The evidence base for Azathioprine in Crohn's Disease and Ulcerative Colitis includes RCTs and substantial long-term observational studies. Research examined maintenance of clinical remission and the frequency of relapse. Studies also explored whether steroid-free remission was observed in patients, a finding often described as steroid reduction.

Certainty remains low for some specific areas. For example, findings were mixed in trials that studied for the use of Azathioprine to initially bring actively symptomatic Ulcerative Colitis under control. Also, research on the appropriate duration of follow-up or how to predict which patients maintain remission after withdrawal are areas where evidence is limited.

Frequently Asked Questions (FAQ)

Common questions about Imurel (FAQ)


Q: Is the mechanism of action of Imurel fully understood by researchers?

Official regulatory documents state that the specific mechanisms by which the active ingredient azathioprine works to improve autoimmune diseases are not fully known or understood. The drug’s action is defined by its role as an antimetabolite that interrupts the division of immune cells, but the exact mechanism for its therapeutic effects in these conditions is described as complex.


Q: What are the general signs of a serious side effect from Imurel?

Official patient information describes specific signs patients should be aware of regarding potentially serious side effects. These signs include easy or unexplained bruising or bleeding, yellowing of the skin or eyes (jaundice), and symptoms of a serious infection, such as a high fever or persistent sore throat. These situations are officially noted as requiring immediate medical evaluation.


Q: Is Imurel a steroid medication?

Imurel is not a steroid medication; it belongs to a class of drugs known as immunosuppressive antimetabolites. In clinical settings, the active ingredient is sometimes used as a steroid-sparing agent. This means it is used to potentially reduce the necessary dosage or duration of a separate steroid medicine.


Q: What is the difference between brand-name Imurel and a generic version?

The brand name Imurel contains the active ingredient azathioprine. According to regulatory requirements, generic versions of azathioprine must be bioequivalent to the brand-name product. This means they must contain the same active ingredient, strength, and dosage form, and are anticipated to work similarly in the body.


Q: Are there general expectations for how long a patient might feel better after starting Imurel?

The medicine has a delayed onset of action because it works gradually by affecting the growth of new immune cells. For conditions like Rheumatoid Arthritis, the therapeutic response is described as generally starting after several weeks, typically 6 to 8. Official guidelines often require a minimum trial period of 12 weeks before fully evaluating the drug's effect.


Q: What precautions should be taken before having surgery while on Imurel?

Official patient guidance emphasizes the importance of informing the doctor or anesthetist that a patient is taking Imurel before having any type of surgery or medical procedure. This is a standard precaution that allows the medical team to manage potential drug interactions and adjust the care plan appropriately.


Q: What is the general process for discontinuing Imurel?

The official label confirms that the drug can be discontinued abruptly. However, because of its slow-acting nature, it is noted that delayed effects may be possible after the drug has been stopped.


Q: Can Imurel interact with common over-the-counter pain relievers?

Official regulatory drug lists primarily describe interactions with other prescription medications. For this reason, patient guidance stresses the importance of disclosing to the doctor or pharmacist before starting any new medicine, including over-the-counter pain relievers.


Q: Is it advisable to consume alcohol while taking Imurel?

Official guidance indicates that limiting alcohol consumption is advised, as azathioprine has a known potential for hepatotoxicity (liver damage). This potential adverse effect may be intensified by regular alcohol intake.


Q: Does Imurel interact with herbal supplements or vitamins?

Official patient information indicates that there is generally not enough safety data available regarding the use of herbal remedies, supplements, and complementary medicines with Imurel. It is noted that these products may carry unknown risks for interactions.


Q: Does Imurel affect fertility in men or women?

Official documents contain a general reference to potential impairment of fertility in the Warnings and Precautions section for the drug. Concerns about fertility are typically discussed with a healthcare provider.


Q: Do patients need to take precautions regarding sun exposure while on Imurel?

Because long-term use of Imurel is associated with an increased risk of skin cancer, official patient guidance highlights the use of specific sun precautions. These include reducing strong sunlight exposure, wearing protective clothing, and using a high-factor sunscreen.


Q: Does taking Imurel affect a person's ability to drive?

The medicine will not usually affect a person's ability to drive. Official patient guidance suggests that if side effects occur that impair concentration or judgment, operating machinery or driving is not recommended until improvement is noted.


Q: Where can I find authoritative research evidence about Imurel?

Authoritative, patient-friendly information about Imurel can be found on government-run health sites. Examples include the US National Library of Medicine (MedlinePlus) and the official drug labeling documents provided by regulatory bodies like the FDA or EMA.


Q: Is there a known risk of a withdrawal effect if Imurel is suddenly stopped?

The official label notes that the effects of the medicine are slow-acting and may persist for some time after cessation. Due to this slow action, there is a possibility of delayed effects upon discontinuation, but this is usually a return of the underlying disease activity.


Q: What is the typical shelf life of Imurel tablets?

The typical shelf life for azathioprine tablets is generally described as five years. This duration is valid when the tablets are stored under the recommended conditions, protected from light and moisture.

How should Imurel be stored and disposed of?

How to Store and Dispose of Imurel (Azathioprine)

Official labeling defines strict conditions for the storage and disposal of Imurel tablets.

Storage Requirements

The tablets must be stored at controlled room temperature, typically below 25 C (77 F), and must be protected from light and moisture. To maintain product integrity and stability, Imurel should be kept in its original container with the lid tightly closed.

As a crucial safety measure, the medicine must be stored out of the sight and reach of children at all times.

Disposal and Handling

Due to its classification as a cytotoxic drug, Imurel requires special handling; tablets should not be broken, crushed, or chewed.

Unused or expired tablets must not be discarded in household waste or flushed down the toilet. Instead, disposal must follow official guidelines for hazardous or cytotoxic substances, often requiring the medication to be returned to a pharmacist or an approved pharmaceutical take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Imurel found in:

A-Z Index: